Sentessa Pharmaceuticals

Sentessa Pharmaceuticals appears in Wake-up haul: an Ozempic moment for the brain through Eli Lilly’s source-reported acquisition, described as worth almost $7.8 billion. The episode uses the deal as a market signal that large pharmaceutical companies see Orexin Agonists as a potentially important category.

The page should keep both the name and deal framing source-scoped until another source confirms or corrects them. In this wiki branch, Sentessa matters because it links orexin science to M&A, category-building, and the comparison with GLP-1 Agonists.

Connections

• Eli Lilly - acquirer named in the source.
• Orexin Agonists and Narcolepsy Wake-Sleep Boundary - category and initial medical context.
• GLP-1 Agonists - analogy used to explain why the category attracts attention.